NewCelX Ltd. is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company is headquartered in Zurich, Zuerich and currently employs 1 full-time employees. The company went IPO on 2021-01-29. The firm focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The firm offers products like Quilience, which is a clinical-stage pharmaceutical compound. The company aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The firm also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The firm is a publicly traded company, listing on the NASDAQ.
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for NCEL. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: NCEL is a Sell candidate.
NCEL stock price ended at $2.77 on 金曜日, after dropping 0.72%
On the latest trading day Feb 13, 2026, the stock price of NCEL fell by 0.72%, dropping from $2.74 to $2.77. During the session, the stock saw a volatility of 2.97%, with prices oscillating between a daily low of $2.69 and a high of $2.77. On the latest trading day, the trading volume for NCEL decreased by 46.7K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 12.5K shares were traded, with a market value of approximately $12.6M.